GET DAILY SIGNALSHeartBeam (BEAT) vs. iRhythm (IRTC): Balancing Early Innovation with Proven Scale in Cardiac Monitoring
Key Takeaways
- BEAT is an early-stage, pre-revenue cardiac monitoring developer, while IRTC is a scaled, revenue-generating digital health platform — a sharp contrast in maturity and risk.
- IRTC generates roughly $825 million in trailing revenue and is approaching profitability, whereas BEAT remains in early commercialization with ongoing net losses.
- BEAT carries elevated dilution and cash-burn risk, while IRTC faces headline risk from a disclosed cybersecurity incident and related investigations.
- Tickeron AI Verdict: Based on trend consistency, scale, and relative stability, the AI would currently favor IRTC over BEAT.
- For deeper coverage, explore BEAT Major News and BEAT Today's Price Move, along with IRTC Major News and IRTC Today's Price Move.
- To see how AI-powered strategies are positioned across the market, visit Trending AI Robots.
Introduction
Both BEAT and IRTC operate in the cardiac monitoring space, yet they sit at opposite ends of the growth curve. HeartBeam is commercializing a novel credit-card-sized electrocardiogram (ECG) device, while iRhythm Holdings has built an established ambulatory monitoring franchise around its Zio patch. This stock comparison is relevant for investors weighing an early-stage, high-risk developmental story against a scaled business with proven recurring revenue. Understanding the relative performance and market positioning of each name can help traders and investors assess where risk, momentum, and fundamentals currently align. When I reviewed the data, I also checked this using Tickeron’s AI Screener to see how the stocks compare to others in the industry.
A Closer Look at BEAT
BEAT, or HeartBeam, Inc., is a Santa Clara, California-based medical technology company developing a cable-free, credit-card-sized 12-lead ECG system designed to detect and monitor cardiac conditions outside a healthcare facility. The company holds two FDA clearances for arrhythmia assessment and is pursuing additional indications, including heart attack detection, with clinical studies underway.
Recent market activity has reflected the realities of early commercialization. The stock trades well below its 52-week high, with a market capitalization of only about $23 million, underscoring its micro-cap profile. Sentiment has been pressured by continued net losses, modest cash balances, and the dilution associated with a roughly $11.5 million equity raise earlier this year. Management has pointed to early commercial partnerships in concierge cardiology practices and an extended cash runway into 2027, but revenue remains minimal, and analyst price targets have been revised lower on a slower-than-expected revenue ramp.
IRTC’s Current Position
IRTC, or iRhythm Holdings, Inc., is a San Francisco-based digital healthcare company whose Zio wearable patch provides continuous ambulatory ECG monitoring for arrhythmia detection. The business combines device sales with cloud-based analytics and recurring monitoring services, generating trailing revenue of roughly $825 million.
Recent performance has been mixed. The company delivered strong quarterly results, with revenue growth of about 20%, gross margins above 70%, and adjusted EBITDA margin expansion — bringing it close to GAAP breakeven. It also completed its acquisition of VitalConnect, broadening its platform across ambulatory, inpatient, and hospital-to-home care. However, shares remain down year-to-date, weighed on by a disclosed cybersecurity incident involving patient data, related shareholder investigations, and some insider selling. Analyst consensus nonetheless remains constructive, with a "Strong Buy" rating and price targets above current levels. I’m watching this closely as the integration progresses.
Head-to-Head Comparison
The most defining contrast is scale and maturity. IRTC is an established, near-profitable business with recurring revenue, strong gross margins, and a growing installed base, while BEAT is still proving commercial traction and faces meaningful dilution risk. Growth drivers differ accordingly: IRTC's catalysts include margin expansion, the VitalConnect integration, and coverage decisions, whereas BEAT's upside hinges on regulatory clearances, clinical data, and adoption in concierge cardiology.
Risk profiles diverge sharply. BEAT's primary risks are execution, cash burn, and financing-driven dilution; IRTC's risks are more idiosyncratic, including cybersecurity fallout, litigation, and integration execution. Sector exposure is similar — both are healthcare equipment and digital health names — but sentiment is notably stronger for IRTC, which carries a "Strong Buy" consensus versus a shrinking and more cautious analyst view on BEAT. In terms of relative performance, IRTC offers stability and recurring revenue, while BEAT presents higher volatility and higher potential asymmetry.
AI Assessment
On observable factors such as trend consistency, financial stability, recurring revenue, and relative positioning, Tickeron's AI would currently lean toward IRTC over BEAT. The preference reflects IRTC's established revenue base, approaching profitability, constructive analyst consensus, and more stable market positioning, weighed against BEAT's earlier-stage commercialization, ongoing losses, and dilution pressures. This assessment is probabilistic rather than definitive: near-term catalysts or shifts in momentum for either name could alter the comparison over time. From what I see, the data supports a measured preference here.
Using Tickeron AI Trading Bots
In my research process, I often turn to Tickeron’s AI Trading Bots to observe how automated strategies are responding to evolving market conditions. These bots cover a range of styles and timeframes, offering quantitative context that complements fundamental analysis on names like these two.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Experienced trader focused on market analysis, identifying trading opportunities, and developing custom trading signals based on market trends, price action, and data-driven insights. Join my Trader Club to follow my latest analysis, trading ideas, and active signals: https://tickeron.com/app/trader-club/103/view?tab=active§ion=trades&via=john
BEAT in upward trend: 10-day moving average crossed above 50-day moving average on October 30, 2026
The 10-day moving average for BEAT crossed bullishly above the 50-day moving average on October 30, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 11 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for BEAT just turned positive on October 28, 2026. Looking at past instances where BEAT's MACD turned positive, the stock continued to rise in 36 of 42 cases over the following month. The odds of a continued upward trend are 86%.
Following a +3.42% 3-day Advance, the price is estimated to grow further. Considering data from situations where BEAT advanced for three days, in 170 of 203 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
Bearish Trend Analysis
The 10-day RSI Indicator for BEAT moved out of overbought territory on October 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 22 similar instances where the indicator moved out of overbought territory. In 21 of the 22 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 43 of 45 cases where BEAT's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 90%.
The Momentum Indicator moved below the 0 level on November 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on BEAT as a result. In 82 of 88 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
BEAT moved below its 50-day moving average on November 02, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BEAT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
BEAT broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for BEAT entered a downward trend on October 02, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 17 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 43 (best 1 - 100 worst), indicating steady price growth. BEAT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 53 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.818) is normal, around the industry mean (4.699). P/E Ratio (-0.802) is within average values for comparable stocks, (13.248). Projected Growth (PEG Ratio) (0.290) is also within normal values, averaging (2.133). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (6.065).
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BEAT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 96, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a wireless medical technology company, which focuses on the delivery of health information
Industry ServicestotheHealthIndustry
Advertisement